Form 4: Equillium Inc. Executive Tom Penny Reports Option Repricing and Grant

Principal Accounting Officer Tom Penny reports the repricing of certain stock options and the grant of new options following the lapse of a holding period.

Summary

• On February 14, 2025, Equillium Inc.'s Principal Accounting Officer, Tom Penny, reported transactions involving employee stock options.
• The transactions include the repricing of existing options to a lower exercise price of $0.785 per share, based on the closing price of Equillium's common stock on August 14, 2023.
• The repricing was approved by the Board of Directors on August 7, 2023, and was subject to a holding period that ended on February 14, 2025.
• Penny also acquired new employee stock options at an exercise price of $0.785 per share.
• Penny disposed of existing employee stock options at exercise prices of $2.45, $5.03, $3.86, $2.52 and $1.06.
• The options vest over a period of four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The repricing and granting of options are standard practices, but the disposal of existing options at higher prices could be seen as slightly negative.

Positives

• The repricing of options to a lower exercise price of $0.785 may incentivize the reporting person.
• The grant of new options may incentivize the reporting person.

Negatives

• The disposal of existing options may indicate a lack of confidence in the company's future performance at the previous exercise prices.

Risks

• The value of the options is dependent on the future performance of Equillium's stock price.
• Changes in market conditions or company performance could impact the value of the options.

Management Comments

• The Board of Directors approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023.

Industry Context

Option repricing is a common practice in the biotech industry to incentivize employees when a company's stock price has declined.

Comparison to Industry Standards

• Option repricing is a common practice, especially in volatile sectors like biotechnology, to maintain employee motivation.
• Many companies, such as Amgen and Gilead, have used similar strategies to retain key personnel during periods of stock price underperformance.
• The vesting schedule of 25% on the first anniversary and the remainder in 36 equal monthly installments is a standard vesting schedule.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the exercise of these options.
• Employees holding options may be incentivized by the repricing.

Key Dates

Keywords

Equillium, Stock Options, Repricing, Form 4, Tom Penny, Officer, Equity, Beneficial Ownership